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CELLULAR IMMUNE RESPONSES AGÀINST MELANOMA CELLS.
P.van deJWiel~van Kemenade, A.A.te Velde, F.Hogervorst,
C.J.M.Melief and C.G.Figdor. The Netherlands Cancer 
Institute, Plesmanlaan 121, 1066 CX Amsterdam, the 
Netherlands.
Malignant melanoma is an important model for the study 
of cellular immune responses against cancer cells. We 
have isolated lymphocytes of normal donors in distinct 
fractions by centrifugal élutriation. Two fractions, 
small lymphocytes (SL) and large lymphocytes (LL), were 
found to differ in cytolytic activity against melanoma 
and other tumor cells. The LL appear to be more cyto­
toxic and this cytotoxicity can be enhanced by cultu­
ring with IL-2, whereas SL could hardly be stimulated 
by IL-2.
Cytotoxic T lymphocyte (CTL) clones can be derived 
from peripheral blood of melanoma patients by a mixed 
lymphocyte/tumor culture with irradiated autologous 
tumor cells and cloning in the presence of IL-2. The 
cytotoxic activity of these clones could be blocked 
by two monoclonal antibodies NKI-M6 and NKI-M7, pro­
duced in our laboratory. Biochemical analysis showed 
that NKI-M6 recognizes a proteoglycan consisting of a 
chondriotin sulfate component with a MW of 450 kD and 
a core protein of 250 kD. NKI-M7 recognizes the vitro­
nectin receptor, a structure belonging to the integrin 
family that is involved in adhesion processes.
Recently we have obtained another series of T cell 
clones that are cytolytic to autologous melanoma cells 
after culturing with rIL-4 instead of rIL-2. It appear­
ed that clones cultured with rIL-4 preferentially kill 
autologous melanoma cells as compared to K562, whereas 
clones cultured with rIL-2 kill K562 as well as auto­
logous melanoma cells.
Analysis of the reactivity of the clones cultured in 
vitro may contribute to the knowledge of immunologi- 
cally important structures on melanoma cells*
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Alpha-MELANOCYTE STIMULATING HORMONE IN HUMAN 
MELANOMA TUMOURS AND a-MSH RECEPTOR MODULATION.
GHANEM G and LEJEVNE F .
LOCE, J Bordet Institute, Université librede Bruxelles,
Brussels, Belgium.
The various physiological effects Of a-MSH, mainly on 
CNS and pigmentation in animal models, are well documented in the 
ÜLerature. Only few investigators confirmed similar properties in 
the human. However, ihe possible physiopathological role played by 
this hormone in human melanoma is still poorly defined.
In order to approach this last subject in a manner as complete as 
possible, we have performed, during the past four years, three 
different series of experiments: 1) a-MSH measurements in plasma 
samples from: a. melanoma and other cancer patients, b, whole body 
UVA irradiated healthy adults, c. circadian rhythm determinations 
in melanoma patients and in healthy male adults, 2) a-MSH 
measurements in human melanoma tumours, 3) a-MSH receptor 
expression on human melanoma cells in culture involving: a. a-MSH 
radio-binding assays and b. tyrosinase assay.
Our results show, so far, 1) increased a-MSH levels 
melanoma patients* plasma, a-MSH responsivness to UVA stimulated 
skin, large immunoreactive a-MSH content in melanoma metaslases 
and an a-MSH circadian rhythm in some individuals different from 
cortisol. 2) a-MSH receptor expression in melanoma ceils could be 
increased by various effectors able to stimulate melanogenesis.
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%To study the activation of oncogenes 
in'human melanoma we used two different 
approaches.
Firstly, mutations in the family of 
ras genes (H-, K-, and N-ras) were 
assayed by the polymerase chain reaction 
(PCR) method using oligonucleotide 
probes specific for the various 
mutations at positions 12, 13 and 61 of 
the p21 ras protein. We have 
investigated 46 fresh tumor specimens 
(9 primary tumors and 37 metastases) and 
12 melanoma cell lines from 39 patients.
In the specimens of 7 patients, only 
mutations in the N-ras gene were found.
No mutations could be detected in the 
other ras genes, indicating that in 
melanoma, the N-ras gene is prone to 
activation. In one patient with 
activated N-ras, both the primary tumor 
and the one metastasis contained the 
mutation and in another patient all 14 
metastases were affected, indicating 
that the mutation is an early event in 
carcinogenesis. Since activated ras 
genes have been reported to be capable 
of altering the sensitivity of cells 
to Natural Killer (NK) cells, we 
assayed the lysis of three melanoma cell 
lines with activated N-ra s . No 
significant differences between the NK 
lysis of these cell lines as compared to 
cell lines without N-ras activation were 
found, suggesting that in melanoma, ras 
activation does not contribute to the 
sensitivity of the tumor cells to NK cells.
Secondly, we analyzed the expression 
of 17 proto-oncogenes in the 12 melanoma 
cell lines at the level of mRNA on 
Northern blots. C-myc was the only 
oncogene with variable expression. 
Interestingly, an inverse correlation 
between c-myc expression and the expression 
of the Class I Major Histocompatibility 
Complex (Class I HLA) was found. Down- 
modulation of Class I HLA by c-myc could 
be established by transfection experiments 
using purified c-myc constructs.
Furthermore, we have found that 
regulation by c-myc is highly 
locus-specific and results in a 
Strong down-modulation of the 
expression of HLA B, rather than A 
and C, in cells expressing high levels 
of c-myc. Since HLA Class I proteins
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